



The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
January 21, 2026

Therapeutic Class	Drug Name	DURB Recommendation*
Cytokine and CAM Antagonists		
	<i>Leqselvi (Oral) Tablet</i>	NP/PA
Ophthalmics, Dry Eye Agents		
	<i>Tryptyr (Ophthalmic) Solution</i>	NP/PA
Keratolytics		
	<i>Zelsuvmi (Topical) Gel</i>	NP/PA

*All recommendations apply to the PDL unless explicitly stated otherwise; DURB=Drug Utilization Review Board; P=preferred; NP=non-preferred; PA=prior authorization; PDL=Preferred Drug List; PADL=Providers' Administered Drug List